Aufklappen
Schliessen
Branche BiotechnologieAktienmarkt Sonstige |
|
|
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
| Leser | Medien | |
|---|---|---|---|---|
| ACTIVE BIOTECH Aktien ab 5,80 Euro handeln - Ohne versteckte Kosten! | LYNX | |||
► Artikel lesen | ||||
| 10.12.18 | Active Biotech provides updated information about the company's financial position | 5 | GlobeNewswire (Europe) | |
| PRESS RELEASE
As announced in connection with the interim report for January-September 2018 Active Biotech has requested, from the bank that finances the company's property in Lund, that the... ► Artikel lesen | ||||
| 19.11.18 | Active Biotech's election committee appointed | 3 | GlobeNewswire (Europe) | |
| PRESS RELEASE
In accordance with a decision made by the Annual General Meeting held on May 17, 2018, the Election Committee shall comprise the representatives for the three largest shareholders... ► Artikel lesen | ||||
| 14.11.18 | Active Biotech AB - Interim report January - September 2018 | 6 | GlobeNewswire (Europe) | |
| Third quarter in brief
Active Biotech provides update on laquinimod in Huntington's disease
Active Biotech regains global... ► Artikel lesen | ||||
| 08.11.18 | Active Biotech: New data from the Phase 2 LEGATO-HD study will be presented at HSG 2018 | 2 | GlobeNewswire (Europe) | |
| PRESS RELEASE
New data from the Phase 2 LEGATO-HD study of laquinimod in Huntington's disease will be presented at the scientific conference HSG 2018
Lund Sweden, November 8,... ► Artikel lesen | ||||
| 13.09.18 | Active Biotech: Data from the Phase 2 LEGATO-HD study of laquinimod in Huntington's disease will be presented at "European Huntington's Disease Network (EHDN) plenary meeting 2018" | 6 | GlobeNewswire (Europe) | |
| PRESS RELEASE
Data from the Phase 2 LEGATO-HD study of laquinimod in Huntington's disease will be presented at the scientific conference "European Huntington's Disease Network (EHDN) plenary... ► Artikel lesen | ||||
| 05.09.18 | Teva bails on laquinimod, returns rights to Active Biotech | 26 | Seeking Alpha | |
► Artikel lesen | ||||
| 05.09.18 | Active Biotech regains global rights to development and commercialization of laquinimod | 4 | GlobeNewswire (Europe) | |
| PRESS RELEASELund Sweden, September 5, 2018 - Active Biotech (NASDAQ OMX NORDIC: ACTI) announced today that it regains the global development and commercialization rights to laquinimod from Teva... ► Artikel lesen | ||||
| 09.08.18 | Active Biotech AB - Interim Report January - June 2018 | 6 | GlobeNewswire (Europe) | |
| Second quarter in brief
The company's... ► Artikel lesen | ||||
| 31.07.18 | Active Bio and Teva's laquinimod fails once more, now in Huntington's disease | 24 | FierceBiotech | |
► Artikel lesen | ||||
| 31.07.18 | Active Biotech provides update on laquinimod in Huntington's disease | 4 | GlobeNewswire (Europe) | |
| PRESS RELEASE
Lund Sweden, July 31, 2018 -Active Biotech (NASDAQ OMX NORDIC: ACTI) today provided an update regarding the clinical development of laquinimod by Teva Pharmaceutical... ► Artikel lesen | ||||
| 31.05.18 | Number of shares and votes in Active Biotech | 8 | GlobeNewswire (Europe) | |
| The number of shares and votes in Active Biotech has changed as a result of the recently completed rights issue.
Today, the last trading day of the month, there are in total 145,236,480 shares... ► Artikel lesen | ||||
| 18.05.18 | Annual General Meeting of Active Biotech AB | 8 | GlobeNewswire (Europe) | |
| PRESS RELEASE
The Annual General Meeting of Active Biotech was held on May 17, 2018.
In accordance with the Board of Directors' proposal, it was resolved that no dividend would be... ► Artikel lesen | ||||
| 17.05.18 | Active Biotech AB Interim report January - March 2018 | 4 | GlobeNewswire (Europe) | |
| First quarter in brief
Decision on new share issue with preferential rights for shareholders taken at Extraordinary General Meeting on March 19, 2018
Patent... ► Artikel lesen | ||||
| 04.05.18 | Nasdaq Stockholm AB: Delisting of paid subscription shares in Active Biotech AB (62/18) | 3 | GlobeNewswire | |
| The paid subscription shares in Active Biotech AB will be delisted. Last
trading day for ACTI BTA is May 8, 2018.
Instrument: Paid subscription shares
---------------------------------------
Short... ► Artikel lesen | ||||
| 23.04.18 | Annual Report 2017 Active Biotech AB (publ) | 8 | GlobeNewswire (Europe) | |
| PRESS RELEASE
Active Biotech's Annual Report 2017 is now available för download at www.activebiotech.com (http://www.activebiotech.com).
The Annual Report will only be... ► Artikel lesen | ||||
| 18.04.18 | Active Biotech: Notice of Annual General Meeting of Shareholders | 11 | GlobeNewswire (Europe) | |
| The Board of Directors of Active Biotech AB (publ) has issued a notice to the Annual General Meeting, which is to take place on Thursday, May 17, 2018, at 5 pm at the company's offices, Scheelevägen... ► Artikel lesen | ||||
| 12.04.18 | Active Biotech's partner NeoTX presents new data at AACR demonstrating that ANYARA enhances the efficacy of checkpoint blockade in preclinical models of cancer | 11 | GlobeNewswire (Europe) | |
| PRESS RELEASELund, April 12, 2018 - Active Biotech (NASDAQ STOCKHOLM: ACTI) today announces that its partner NeoTX Therapeutics Ltd. will present new data for ANYARA (Naptumumab Estafenatox) at... ► Artikel lesen | ||||
| 27.03.18 | Nasdaq Stockholm AB: Listing of subscription rights and paid subscription shares in Active Biotech AB (38/18) | 7 | GlobeNewswire | |
| With effect from March 28, 2018, the subscription rights in Active Biotech AB
will be quoted on the list for Equity rights. Quotation will continue up until
and including April 9, 2018.
Instrument:... ► Artikel lesen | ||||
| 22.03.18 | NASDAQ OMX Nordic: Derivatives: Adjustment in Active Biotech due to rights issue (02/18) | 4 | GlobeNewswire | |
| Extraordinary General Meeting (EGM) of Active Biotech AB (Active Biotech) held
on March 19, 2018, approved a rights issue whereby shareholders are entitled to
one (1) new share for every two (2) shares... ► Artikel lesen | ||||
| 22.03.18 | XFRA CAPITAL ADJUSTMENT INFORMATION - 23.03.2018 - 1 | 61 | Xetra Newsboard | |
| FOLGENDE WERTPAPIERE WERDEN AM 22.03.2018 CUM KAPITALMASSNAHME UND AM 23.03.2018 EX KAPITALMASSNAHME GEHANDELT. THE FOLLOWING SHARES ARE TRADED CUM CAPITAL ADJUSTMENT ON 22.03.2018 AND EX CAPITAL ADJUSTMENT... ► Artikel lesen | ||||
Seite:
1 2 Weiter >>
23 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten:
VerkaufenHaltenKaufen
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | |
|---|---|---|---|---|
| EVOTEC | 19,705 | +1,05 % | Evotec und Morphosys mit deutlichen Verlusten - ist die Rallye bereits zu Ende? | |
| Nachdem die Aktien von Morphosys und Evotec im Wochenvergleich besonders stark gelaufen waren, müssen sie zum Start der neuen Woche eine Korrekturbewegung hinnehmen. Morphosys ist im Wochenvergleich... ► Artikel lesen | ||||
| MEDIGENE | 8,98 | -0,33 % | Medigene: Hoher Multiplikatoreffekt | |
| Die Medigene-Aktie scheiterte erneuert am Widerstand bei 10 Euro. Risikobereite Biotech-Anleger bleiben bei dem Immuntherapie-Spezialisten dennoch weiter am Ball. Denn: Das Besondere an den verschiedenen... ► Artikel lesen | ||||
| MORPHOSYS | 101,40 | -0,88 % | Goldman belässt Morphosys auf 'Neutral' - Ziel 114 Euro | |
| Die US-Investmentbank Goldman Sachs
hat die Einstufung für Morphosys auf "Neutral" mit einem Kursziel
von 114 Euro belassen. Es sei sehr positiv, dass der
Entwicklungspartner Janssen für das Schuppenflechte-Mittel... ► Artikel lesen | ||||
| BB BIOTECH | 60,50 | -0,90 % | BB Biotech nach Celgene-Hüpfer: Folgt schon bald die nächste prominente Übernahme? | |
| Die Aktie von BB Biotech (WKN: A0NFN3) ist definitiv erfolgreich ins neue Börsenjahr gestartet. Bereits nach wenigen Handelstagen notierte die Beteiligungsgesellschaft gut zweistellig im Plus. Die angekündigte... ► Artikel lesen | ||||
| QIAGEN | 32,31 | +1,00 % | Qiagen besser als Evotec und Morphosys? | |
| Betrachtet man die heutige Kursperformance im MDAX, dann ist die Frage klar mit ja zu beantworten. Die Aktie von Qiagen legt 1,4 Prozent zu und ist damit der beste Biotech-Wert des Tages im Index. Evotec... ► Artikel lesen | ||||
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und mit der Push-Technologie von
Nachrichten • Aktienkurse • DAX • Xetra-Orderbuch • Watchlist
Ad hoc-Mitteilungen • Nachrichten Börsen • Aktien-Empfehlungen
Branchen • Medien • Nachrichten-Archiv
Impressum | AGB | Disclaimer | Datenschutz • Presse • Mediadaten
RSS-News von FinanzNachrichten.de kostenlos für Ihren Browser und Ihre Homepage